|
Possible nitric oxide mechanism involved in the protective effect of L-theanine on haloperidol-induced orofacial dyskinesia
Cheng-Chia Tsai1, Mao-Hsien Wang2, Kuo-Chi Chang3, Hung-Sheng Soung4, Chih-Chuan Yang1, Hsiang-Chien Tseng5
1 Department of Neurosurgery, Mackay Memorial Hospital, Taipei, Taiwan, ROC
2 Department of Anesthesia, En Chu Kon Hospital, Sanshia District, New Taipei City, Taiwan, ROC
3 Department of Chemical Engineering and Biotechnology, National Taipei University of Technology, Taipei, Taiwan, ROC
4 Department of Psychiatry, Yuan-Shan Branch of Taipei Veteran General Hospital, Yilan County; Department of Biomedical Engineering, National Defense Medical Center, Taipei, Taiwan, ROC
5 Department of Anesthesiology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei; School of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan, ROC
Correspondence Address:
Dr. Hsiang-Chien Tseng
Department of Anesthesiology, Shin Kong Wu Ho-Su Memorial Hospital, No. 95, Wenchang Road, Shilin Dist., Taipei 11101, Taiwan
ROC
 Source of Support: None, Conflict of Interest: None  | 6 |
DOI: 10.4103/CJP.CJP_8_19
|
|
Having powerful antioxidative properties, L-theanine (LT), one of the major amino acid components in green tea, has potent anti-oxidative and neuroprotective effects. In this study, we examined the potential protective effects of LT on haloperidol (HAL)-induced orofacial dyskinesia (OD) in rats. HAL treatment (1 mg/kg intraperitoneally for 21 days) induced OD; significant increases (P < 0.001) in the frequency of vacuous chewing movement and tongue protrusion as well as the duration of facial twitching. LT treatment (100 mg/kg orally for 35 days, starting 14 days before HAL injection) was able to prevent most of the HAL-induced OD. LT treatment was also able to reduce the lipid peroxidation production and nitric oxide (NO) level, and enhance the antioxidation power in striatum from rats with HAL treatment. In order to examine the implication of NO pathway activity in HAL treatment, either NO precursor (L-arginine) or NO synthase inhibitor (L-NAME) was co-pretreated with LT; NO precursor treatment eliminated the protective effect of LT, in contrast to that NO synthase inhibitor treatment significantly potentiated the LT effects on behavioral and biochemical protection in HAL-treated rats. These results suggested that the NO pathway was implicated, at least in part, in the HAL-induced OD, as well as in the protective effect of LT in treating HAL-induced OD. The above evidence provides a clinically relevant value for LT in delaying or treating tardive dyskinesia.
|
